Refeyn launches MyMass instrument to simplify sample quality assessment for structural biology

Structure-based drug design and AI-driven therapeutic development are transforming how new medicines are discovered, but depend on high-quality samples. Structural and biophysical workflows, such as cryo-EM, native mass spectrometry (MS), bio-layer interferometry (BLI), and surface plasmon resonance (SPR), are time-consuming and costly, and poor sample quality remains one of the main reasons they fail. MyMassMP gives researchers a fast, accurate assessment of purity, homogeneity, and oligomerization state in solution before committing to resource-intensive experiments.

Built on the same proven technology as Refeyn's TwoMP mass photometer, which is already trusted across leading structural biology and biotherapeutics labs worldwide, MyMassMP brings this quality check capability into a simpler, self-contained benchtop instrument. Featuring an integrated display and computer for onboard data analysis, and dedicated consumables, it offers an intuitive workflow from sample to result.

Gerry Mackay, CEO, RefeynStructural biology and AI-driven drug discovery are moving fast, but they're only as good as the samples that drive them. MyMass directly addresses that challenge and marks a significant step forward for Refeyn, putting the power of mass photometry within reach of more researchers than ever before,"

Fiona Coats, Chief Product and Marketing Officer at Refeyn, said: "In recent years, our users have consistently shown us how valuable mass photometry is for quickly assessing sample quality before committing to more complex experiments. With MyMassMP, we're making this capability even more accessible - empowering researchers to confidently answer a simple but critical question: Are my samples ready?"

Source:

Refeyn